A5033471083- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Bladder and Urothelial Cancer Treatments
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Insect-Plant Interactions and Control
- Lung Cancer Treatments and Mutations
- Glycosylation and Glycoproteins Research
- Angiogenesis and VEGF in Cancer
- Trypanosoma species research and implications
- Toxoplasma gondii Research Studies
- Radiopharmaceutical Chemistry and Applications
- Forest Insect Ecology and Management
- Advanced Breast Cancer Therapies
- Systemic Lupus Erythematosus Research
- Neurobiology and Insect Physiology Research
- Insect Resistance and Genetics
- Tryptophan and brain disorders
- Peptidase Inhibition and Analysis
- Liver physiology and pathology
- Cancer, Hypoxia, and Metabolism
- Autophagy in Disease and Therapy
- Complement system in diseases
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
Tongji University
2016-2025
State Key Laboratory of Mobile Networks and Mobile Multimedia Technology
2022-2024
Tongji Hospital
2016-2023
State Forestry and Grassland Administration
2020-2023
Jilin Provincial Academy of Forestry Science
2011-2023
AstraZeneca (United States)
2023
AstraZeneca (United Kingdom)
2023
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
ZTE (China)
2022
China Mobile (China)
2022
Abstract Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E, in patients HER2+ locally advanced or metastatic urothelial carcinoma (mUC) refractory to standard therapies. Patients Methods: This was phase II, open-label, multicenter, single-arm study (IHC status 3+ 2+) mUC who previously failed at least one line systemic chemotherapy. The primary endpoint objective response rate (ORR) assessed by blinded...
Abstract Background Current treatment options for human epidermal growth factor receptor 2 (HER2)‐overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there is no specific HER2 immunohistochemistry (IHC) 2+ and fluorescence in‐situ hybridization‐negative patients. Here, we report the efficacy safety of a novel anti‐HER2 antibody RC48 patients with HER2‐overexpressing, advanced or gastroesophageal junction cancer. Methods Patients HER2‐overexpressing (IHC...
Abstract Purpose RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated to MMAE via a cleavable linker. A phase I study was initiated evaluate toxicity, MTD, PK, and antitumor activity of in patients with HER2-overexpressing locally advanced or metastatic solid carcinomas, particularly gastric cancer. Patients methods This 2-part study. Successive cohorts received escalating doses (0.1 mg/kg, 0.5 1.0 2.0 2.5 3.0 mg/kg). Dose expansion proceeded at dose mg/kg Q2W. The...
To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients HER2-positive locally advanced or metastatic urothelial carcinoma (UC) refractory to standard regular therapies.
Although the antibody-drug conjugates (ADCs) have significantly improved survival outcomes of patients with human epidermal receptor 2 (HER2)-expressing gastric or gastroesophageal junction (G/GEJ) cancer, efficacy ADC used as a single agent is limited. Therefore, it necessary to investigate effective and safe combination regimens. Preclinical data indicated synergetic antitumour effect RC48 programmed cell death protein 1 (PD-1) inhibitors. We aimed evaluate safety plus toripalimab in...
665 Background: This single-arm phase II trial was conducted to evaluate the efficacy and safety of neoadjuvent disitamab vedotin (DV, a HER2-targetted monoclonal antibody conjugated with monomethyl auristatin E) plus perioperative toripalimab (an anti-PD-1 inhibitor) in MIBC patients (pts) HER2 expression. The preliminary results showed promising acceptable neoadjuvant treatment DV pts HER2-expressing (Sheng, et al. ASCO Annual meeting 2024). Methods: Key eligibility criteria included...
Among the earliest and most important stages during tumorigenesis is activation of angiogenic process, an event that termed “switch to phenotype.” We have developed in vivo system can reliably recapitulate tumor development represent this transition. Using model, we harvested studied nodules be distinguished from each other on basis their degree vascularization. Angiogenic were characterized by presence capillary vessels as determined factor VIII immunohistochemistry, both proteolytic...
Toxoplasma gondii belongs to the phylum Apicomplexa and is an important cause of congenital disease infection in immunocompromised patients. Like most apicomplexans, T. possesses several plant-like features, such as chloroplast-like organelle, apicoplast. We describe characterize a novel organelle tachyzoites, which visible by light microscopy broad similarity plant vacuole. Electron tomography shows interaction this vacuole with other organelles. The presence vacuolar proton pyrophosphatase...
1022 Background: Currently, there are no standard ≥3 line regimens recommended for HER2-positive (IHC 3+, or IHC 2+/FISH+) advanced metastatic breast cancer, and HER2-targeting treatment HER2-low expressing 2+/FISH-, 1+) population. RC48-ADC is an innovative antibody-drug conjugate with a cleavable linker potent microtubule inhibitor payload MMAE that has bystanding effect in tumor cell killing. Methods: C001 CANCER (NCT02881138) was dose-escalation phase I study (0.5, 1.0, 1.5, 2.0, 2.5...
This phase 2b, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of telitacicept, a novel fusion protein that neutralises signals B lymphocyte stimulator proliferation-inducing ligand, in active systemic lupus erythematosus (SLE).
Abstract Objective To evaluate the efficacy and safety of telitacicept in adult patients with primary SS (pSS) a phase II randomized double-blind placebo-controlled trial. Methods Patients pSS positive anti-SSA antibody ESSDAI ≥ 5 were randomly assigned, 1:1:1 ratio, to receive weekly subcutaneous 240 mg, 160 or placebo for 24 weeks. The end point was change from baseline at week 24. Safety monitored. Results A total 42 enrolled (n = 14 per group). Administration mg resulted significant...
Triple-negative breast cancer (TNBC) remains the most lethal form of cancer, and effective targeted therapeutics are in urgent need to improve poor prognosis TNBC patients. Here, we report development a rationally designed antibody drug conjugate (ADC) for treatment late-stage refractory TNBC. We determined that intercellular adhesion molecule-1 (ICAM1), cell surface receptor overexpressed TNBC, efficiently facilitates receptor-mediated internalization. next constructed panel four ICAM1 ADCs...
Abstract Background Disitamab vedotin (DV; RC48‐ADC) is an antibody‐drug conjugate comprising a human epidermal growth factor receptor 2 (HER2)‐directed antibody, linker and monomethyl auristatin E. Preclinical studies have shown that DV demonstrated potent antitumor activity in preclinical models of breast, gastric, ovarian cancers with different levels HER2 expression. In this pooled analysis, we report the safety efficacy patients HER2‐overexpression HER2‐low advanced breast cancer (ABC)....
This study describes the identification of Drosophila yellow-f and yellow-f2 as dopachrome-conversion enzymes responsible for catalysing conversion dopachrome into 5,6-dihydroxyindole in melanization pathway. Drosophilayellow-y gene yellow-b, -c, -f -f2 genes were expressed an insect cell/baculovirus expression system their corresponding recombinant proteins screened enzyme activity. Among yellow yellow-related genes, identified coding based on high activity production from dopachrome. Both...
Antibody-drug conjugate (ADC) is a novel class of therapeutics for cancer target therapy. This study assessed antitumor activity ADC with an antimitotic agent, monomethyl auristatin E (MMAE) and humanized monoclonal anti-HER2 antibody, hertuzumab, in gastric cancer. The efficacy hertuzumab-MC-Val-Cit-PAB-MMAE (hertuzumab-vcMMAE) on human epidermal growth factor receptor 2 (HER2) positive cells, NCI-N87, was evaluated vitro vivo. cytotoxicity hertuzumab significantly enhanced after...
IntroductionTelitacicept, a transmembrane activator and cyclophilin ligand (CAML) interactor (TACI) fusion protein targeting B cell activating factor (BAFF) proliferation-inducing (APRIL), has proven efficacy in treating Immunoglobulin A (IgA) nephropathy. However, serum biomarkers that could predict the clinical response during treatment remain unclear.MethodsPlasma samples from 24 participants Phase 2 trial were collected at baseline after 4, 12, weeks, 8 placebo group, 9 160 mg 7 240...
Objective. Matrix metalloproteinases (MMPs) and the angiogenic proteins basic fibroblast growth factor (bFGF) vascular endothelial (VEGF) have been implicated in mechanisms of human cancer metastasis. Assays were conducted on urine patients with anomalies (tumors malformations), relatively common occasionally life-threatening disorders for which few therapies exist. We sought to determine whether these angiogenesis modulators are present their expression is associated extent clinical course...